Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Induction Chemotherapy + RT vs Induction + CCRT in Locoregionally Advanced NPC
NCT05527470Phase 3Recruiting
- Start
- Nov 2022
- Primary completion
- Nov 2025
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of gemcitabine and Cisplatin micelle injection (HA132) in nasopharyngeal carcinoma (NPC) (2 arms). Primary endpoint: Progression-free Survival at 3 years. Started Nov 2022; status: recruiting.
02
Drugs
gemcitabineCisplatin micelle injection (HA132)
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT05527470.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05527470.